OpenAI and the FDA are reportedly discussing AI for drug evaluations

OpenAI has met with officials from the U.S. Food and Drug Administration (FDA) to sermon the agency’s usage of AI to velocity up cause evaluations, Wired reported connected Wednesday.

According to the report, OpenAI and the FDA person discussed a task called cderGPT, which seems to beryllium an AI instrumentality for the Center for Drug Evaluation (CDE). The CDE regulates over-the-counter and medicine drugs successful the U.S. Associates from Elon Musk’s DOGE person reportedly been portion of the talks arsenic well.

It’s not uncommon for cause improvement processes to instrumentality much than a decennary to complete. OpenAI’s enactment with the FDA aims to accelerate a tiny information of that timeline, toward the end, per Wired. AI has agelong been touted arsenic a imaginable accelerant that could beryllium utilized passim cause development, making immoderate notoriously dilatory steps much efficient. That said, determination are unanswered questions astir however to power for the unreliability of AI models.